GALT Stock — Galectin Therapeutics Inc

Galectin Therapeutics Inc (GALT)

Updated October 16, 2026.

GALT is a Stock. Total return is -69.8% over the past 24.1 years, 1293.9 points behind SPY at 1224.1%.

Galectin Therapeutics is a clinical-stage biopharmaceutical company developing therapies for fibrotic disease and cancer, with its lead program belapectin (GR-MD-02), a galectin-3 inhibitor currently in Phase 2 clinical trials for metabolic dysfunction-associated fatty liver disease (MASH) with advanced fibrosis and cirrhosis. The company does not currently distribute to shareholders. This security appeals primarily to investors with high risk tolerance who are interested in early-stage biotech development rather than current income.

GALT performance versus SPY

Price and return data through 2026-10-16.

Total return is -69.8% over the past 24.1 years, 1293.9 points behind SPY at 1224.1%. Over the past year its total return — price change plus distributions reinvested — is -28.3%. Its deepest 1-year drawdown was 68.0%.

GALT key facts

Asset type

Stock

Asset class

Equity

Inception date

09/04/2002

Distribution frequency

None

Last close

$3.62 (as of 2026-10-16)

Market cap

$365,075,711

Average volume

169419.0

Beta

0.381

Payout ratio

0.0%

Forward P/E

4.5434

EPS

$-0.43

How Dividend Vision calculates yield and returns

Distribution rate (the posted rate) uses calculation basis unavailable. Issuer rates can use a different denominator and date, including ex-date NAV. Trailing-12-month yield is the sum of split-adjusted cash distributions with ex-dates in the last 12 months, divided by the published price. It lags a recent raise or cut. Total return uses split-adjusted close with distributions reinvested on the ex-dividend date (a modeling convention, not the cash-settlement date) from the first stored bar on or after inception through the latest bar, compared with the same window on the benchmark. That is the security's total return, not your personal gain/loss.

Yield and safety methodology · Distribution rate methodology · Distribution Safety Score methodology

Sources and review

Primary sources: prices and distributions from Dividend Vision, derived from vendor EOD data.

Reviewed by Bert Sweet, CEO and Co-owner of Dividend Vision. Methodology: Distribution Safety Score.

GALT risks and drawbacks

Total return has trailed SPY over the available window. The deepest 1-year drawdown on record here is 68.0%.

Who may consider GALT — and who may not

It is a weaker fit for investors who need monthly cash flow (GALT does not currently distribute); investors whose main goal is matching SPY total return. This is educational context, not a recommendation to buy or sell.

More on GALT

• All tickers starting with G

Tagged: Healthcare.

Frequently asked questions